165668-35-9

Upstream product

• 2942-42-9 7-Nitroindazole 
• 21443-96-9 1H-indazol-7-amine 
• 98-68-0 4-methoxy-phenyl-sulphonyl chloride 
• 64-17-5 ethanol 

Downstream Products

• 865604-02-0 4-methoxy-N-methyl-N-(3-bromo-4-(4-methoxyphenyl)-1-methyl-7-indazolyl)benzenesulfonamide 
• 865603-95-8 N-(3,4-diiodo-1H-indazol-7-yl)-4-methoxy-N-methyl-benzenesulfonamide 
• 865603-96-9 4-methoxy-N-methyl-N-(3,4-diiodo-1-methyl-7-indazolyl)benzenesulfonamide 
• 865604-00-8 N-(3-bromo-4-iodo-1H-indazol-7-yl)-4-methoxy-N-methyl-benzenesulfonamide 
• 865604-01-9 N-(3-bromo-4-iodo-1-methyl-1H-indazol-7-yl)-4-methoxy-N-methyl-benzenesulfonamide 
• 865603-94-7 N-(4-iodo-1H-indazol-7-yl)-4-methoxy-N-methyl-benzenesulfonamide 
• 865603-97-0 4-methoxy-N-methyl-N-(7-indazolyl)benzenesulfonamide 
• 865603-87-8 4-methoxy-N-(4-iodo-7-indazolyl)benzenesulfonamide 

Relevant academic research and scientific papers

Synthesis and biological evaluation of N-(7-indazolyl)benzenesulfonamide derivatives as potent cell cycle inhibitors

We herein describe a new synthesis of N-(7-indazolyl)benzenesulfonamide derivatives. These compounds were evaluated for their antiproliferative activities toward L1210 murine leukemia cells. One of them, 4-methoxy-N-(3- chloro-7-indazolyl)benzenesulfonamide, was identified as the most potent with an IC50 of 0.44 μM.

New and efficient synthesis of bi- and trisubstituted indazoles

In this paper, the synthesis of bi- and trisubstituted indazoles was described. 4-Alkoxy-7-aminoprotected-indazole or 7-aminoprotected-indazole derivatives were prepared selectively using SnCl2 in alcohol or SnCl2 in ethyl acetate, r

Synthesis of 4-substituted and 3,4-disubstituted indazole derivatives by palladium-mediated cross-coupling reactions

The synthesis of 4-substituted indazole derivatives by palladium-mediated cross-coupling reactions was described. Suzuki, Heck, Sonogashira and Stille cross-coupling reactions were used to introduce aryl, vinyl and alkynyl substituents in 4-position of in

Integrin expression inhibitors

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR4bR5b)mb— (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.